Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flow from operating activities:
Net income (loss)	$ 14,192	$ (100,118)
Adjustments to reconcile net income (loss) to net cash used in operations:
Depreciation and amortization	9,436	8,817
Non Cash Lease Expense	(59)
Deferred income taxes	(1)	(1,353)
Provision for doubtful accounts	1,877	298
Change in fair value of warrant liabilities	(42,109)	(13,482)
Inventory reserve for obsolescence	904
Goodwill impairment	3,610
Stock-based compensation expense	15,856	40,010
Change in fair value of contingent consideration	(126,277)	(41,145)
Change in fair value of debt	2,522
Issuance of common stock to settle liability with CTH		5,333
Change in fair value of contingent stock consideration	186
Other, net	(37)	2,627
Changes in assets and liabilities:
Accounts receivable	(3,584)	(1,909)
Inventory	(16,891)	(6,422)
Prepaid expenses and other assets	49	3,068
Sale of net operating losses and research and development tax credits		1,356
Accounts payable	(2,948)	3,007
Accrued expenses and other liabilities	4,710	(1,801)
Right-of-use assets and lease liabilities	263
Deferred revenue	425	(8,382)
Net cash used in operating activities	(137,876)	(110,096)
Cash flow from investing activities:
Capital expenditures	(5,236)	(6,203)
Proceeds from promissory note		300
Net cash used in investing activities	(5,236)	(5,903)
Cash flow from financing activities:
Proceeds from the exercise of warrants	46,491
Proceeds from short-term debt	39,200
Proceeds from the sale of common stock in ATM offering	6,519
Payments of ATM offering costs and commissions	(498)
Proceeds from short term borrowings - related party		5,000
Payment of short term borrowings - related party		(5,000)
Cash received on recapitalization		5,386
Proceeds from Palantir investment		20,000
Proceeds from PIPE financing	30,000	83,400
Proceeds from the exercise of stock options	862	638
Tax withholding on vesting of restricted stock units	(132)
Payments of PIPE/SPAC related costs	(2,604)	(10,862)
Net cash provided by financing activities	119,838	98,562
Net (decrease) increase in cash, cash equivalents and restricted cash	(23,274)	(17,437)
Cash, cash equivalents and restricted cash at beginning of year	52,076	69,513
Cash, cash equivalents and restricted cash at end of year	28,802	52,076
Supplemental disclosure of cash flow information:
Cash paid for interest		146
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	(683)	(970)
Common stock issued for short-term debt conversion	4,099
Recapitalization from merger		550,113
Cancellation of treasury stock		256
Non-cash assets acquired from the merger		163
Warrant liability assumed from the merger		59,202
Issuance of common stock as payment for PIPE/merger related costs		10,795
Reclassification of warrant liabilities to equity		96,398
Reclass of offering costs paid in prior year		$ 153
Reclassification Of Option Liabilities To Equity	$ 441